Neoadjuvant versus perioperative immunotherapy in resectable NSCLC: A PD-L1-stratified Bayesian network meta-analysis.

Jian Y, Wu Z, Lai F, Wei M, Cao J, Jia P, Li M, Qing C, Yang F, Wang K

Open source

DOI
10.3389/fonc.2026.1905730
Published
2026
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1905730,
  title = {Neoadjuvant versus perioperative immunotherapy in resectable NSCLC: A PD-L1-stratified Bayesian network meta-analysis.},
  author = {Jian Y and Wu Z and Lai F and Wei M and Cao J and Jia P and Li M and Qing C and Yang F and Wang K},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1905730},
  url = {https://doi.org/10.3389/fonc.2026.1905730}
}

RIS

TY  - JOUR
TI  - Neoadjuvant versus perioperative immunotherapy in resectable NSCLC: A PD-L1-stratified Bayesian network meta-analysis.
AU  - Jian Y
AU  - Wu Z
AU  - Lai F
AU  - Wei M
AU  - Cao J
AU  - Jia P
AU  - Li M
AU  - Qing C
AU  - Yang F
AU  - Wang K
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1905730
UR  - https://doi.org/10.3389/fonc.2026.1905730
ER  - 

APA

Y, J., Z, W., F, L., M, W., J, C., P, J., M, L., C, Q., F, Y., & K, W. (2026). Neoadjuvant versus perioperative immunotherapy in resectable NSCLC: A PD-L1-stratified Bayesian network meta-analysis.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1905730

Source records